<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04908605</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU MS251 /202l</org_study_id>
    <nct_id>NCT04908605</nct_id>
  </id_info>
  <brief_title>Emergence Agitation After Nasal Surgery: a Randomized Controlled Comparison Between Melatonin and Mirtazapine</brief_title>
  <official_title>Emergence Agitation After Nasal Surgery: a Randomized Controlled Comparison Between Melatonin and Mirtazapine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Emergence agitation (EA) is common after nasal surgery under general anesthesia, which can&#xD;
      lead to several problems, such as increased risk of injury to the patient or medical staff,&#xD;
      pain, decreased patient satisfaction, hemorrhage, re-bleeding at the operation site and&#xD;
      unplanned self-extubation.&#xD;
&#xD;
      Melatonin is an oral or sublingual medication, most commonly used for insomnia and improving&#xD;
      sleep in different conditions for example shift-work disorder and for helping people to&#xD;
      establish a day and night cycle especially blind children or adults.&#xD;
&#xD;
      Mirtazapine is an antidepressant used in medicine in a pill form, most commonly used for&#xD;
      major depressive disorder and other mood disorders, relief of anxiety, panic disorders,&#xD;
      insomnia, headache and migraine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of patients with the Riker sedation-agitation score ≥5</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Total number of patients with the Riker sedation-agitation score ≥5</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Agitation</condition>
  <arm_group>
    <arm_group_label>Mirtazapine group (Group I) (n=55)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Melatonin group (Group II) (n=55)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group (Group III) (n=55)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirtazapine</intervention_name>
    <description>Every patient will be given mirtazapine 30 mg tablet</description>
    <arm_group_label>Mirtazapine group (Group I) (n=55)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>Every patient will be given melatonin 5 mg tablet</description>
    <arm_group_label>Melatonin group (Group II) (n=55)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Every patient will be given a matching placebo tablet</description>
    <arm_group_label>Placebo group (Group III) (n=55)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients according to American Society of Anesthesiologists physical status&#xD;
             classification (ASA) I or II.&#xD;
&#xD;
          2. Patients according to Mallampati classification I or II.&#xD;
&#xD;
          3. Patients accepting the study and consenting.&#xD;
&#xD;
          4. Undergoing general anesthesia for elective nasal surgery in which nasal packing on&#xD;
             each side was used until 24 h after surgery.&#xD;
&#xD;
          5. Body mass index(BMI)&lt;30&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient's refusal.&#xD;
&#xD;
          2. Known allergy to any of the study medications.&#xD;
&#xD;
          3. History of obstructive sleep apnea.&#xD;
&#xD;
          4. History of psychiatric illness or intake of antipsychotics.&#xD;
&#xD;
          5. History of liver impairment.&#xD;
&#xD;
          6. Pregnancy.&#xD;
&#xD;
          7. History of uncontrolled hypertension.&#xD;
&#xD;
          8. History of renal disease.&#xD;
&#xD;
          9. Body mass index (BMI) ≥30 kg/m2.&#xD;
&#xD;
         10. Contraceptive drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ibrahim Mamdouh Esmat</last_name>
    <phone>01001241928</phone>
    <email>ibrahim_mamdouh@med.asu.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain-Shams University Hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ibrahim Mamdouh Esmat</last_name>
      <email>ibrahim_mamdouh@med.asu.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Dr.Ibrahim Mamdouh Esmat</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesia and Intensive Care Department, Faculty of Medicine, Ain- shams University, Cairo, Egypt.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Emergence Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Mirtazapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

